Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 6Phase 1/2 4Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 5Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 18Neoplasms 16Prostatic Neoplasms 12Neoplasm Metastasis 10Pain 9Colorectal Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 8Polycystic Ovary Syndrome 7Leiomyoma 6Anemia 5Skin Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia 4Carcinoma, Renal Cell 4Recurrence 3Melanoma 3Liver Neoplasms 3Kidney Neoplasms 3Keratosis, Actinic 3Insulin Resistance 3Carcinoma, Hepatocellular 3Cancer Pain 3Brain Neoplasms 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2

Interventions

blinatumomab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Terminated × Neoplasm, Residual × Clear all
NCT04506086 2025-05-18

Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 4 Terminated
10 enrolled 12 charts
LymphoidOther hematologic neoplasm

Leukemia, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡